Viking Therapeutics VKTX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's additional paid-in capital?
- Viking Therapeutics (VKTX) reported additional paid-in capital of $1.51B in Q1 2026.
- How has Viking Therapeutics's additional paid-in capital changed year-over-year?
- Viking Therapeutics's additional paid-in capital increased by 9.3% year-over-year, from $1.38B to $1.51B.
- What is the long-term trend for Viking Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Viking Therapeutics's additional paid-in capital has grown at a 29.2% compound annual growth rate (CAGR), from $412.59M to $1.49B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.